Skip to content
GLP-1 Scorecard
Menu
Graded #384

MEDVidi

MEDVidi is a US telehealth platform whose licensed providers evaluate patients and prescribe GLP-1 weight-management medications, including brand-name Zepbound (tirzepatide) and Wegovy (semaglutide), plus…

Visit MEDVidiWe may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Semaglutide
Not disclosed
Tirzepatide
Not disclosed
Coverage
Coverage not published
Brand-name
Yes

Line MEDVidi up against its closest alternatives.

Factor breakdown

Each of the six graded dimensions. See the methodology.

Cost value45/100
Dose & formulation53/100
Clinical oversight77/100
Labs & monitoring62/100
Fulfillment59/100
Contract terms55/100

Strengths

  • Licensed providers can prescribe brand-name Zepbound and Wegovy
  • Transparent flat consultation fees (195 dollar initial, 159 dollar follow-up)
  • Prescriptions sent to the patient's pharmacy of choice, so insurance can be used

Where it loses points

  • Consult-fee model: medication is not included and its cost is separate
  • No medication pricing is published
  • State list is shown as a map rather than enumerated

Bottom line — Grade C

Best for: People who want a licensed provider to prescribe brand glp-1 they fill with insurance.

Ranked #384 of 499 on this scorecard. See our top-scoring pick, CoreAge Rx (#1), for comparison.

Closest on the board

The boards grading nearest MEDVidi — the realistic shortlist.

The 20 boards nearest this one

View full scorecard rankings →

Pricing/verification reflect MEDVidi's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on MEDVidi's site. Not medical advice; see our disclosure.

← Back to the scorecard